TCMBANKIN000234 |
bisabolangelone |
bisabolangelone |
C15H20O3 |
248.32 g/mol |
CC1=CC(=O)C2C(C1)OC(=CC=C(C)C)C2(C)O |
TCMBANKIN001301 |
Pimpinellin |
pimpinellin |
C14H16O9 |
328.27 |
COC1=C(C2=C(C=CO2)C3=C1C=CC(=O)O3)OC |
TCMBANKIN015931 |
Sphondin |
Spectrum_000598; sphondin ; CCG-38810; SDCCGMLS-0066509.P001; CHEMBL1452868; MolPort-000-882-157; SR-01000711830-2; A4338/0184974; SPBio_001898; W1276; Sfondin; ZINC3197732; Spectrum3_001238; Spectrum5_000320; 6-Methoxy-2H-furo[2,3-H]chromen-2-one; NCGC00095567-02; ST097615; ST4140655; BRD-K33260002-001-02-0; 4CN-1365; 6-Methoxy-2H-furo(2,3-h)-1-benzopyran-2-one; BSPBio_002716; MLS000574845; 6-Methoxy-2H-furo[2,3-H]chromen-2-one #; KBioSS_001078; Spectrum4_001600; 4-methoxyfurano[2,3-h]chromen-8-one; SCHEMBL9794931; KBioGR_002220; NCGC00095567-01; SR-01000711830; KBio2_003646; HMS3340O03; DLCJNIBLOSKIQW-UHFFFAOYSA-N; 483-66-9; SpecPlus_000144; KBio3_002216; NCGC00178511-01; 6-methoxy-2-furo[2,3-h]chromenone; KBio2_001078; MCULE-1142431458; SMR000156215; BG01521509; Spectrum2_001759; sphondin; KBio2_006214; HMS2218E05; KBio1_001184; 6-Methoxyfuro[2,3-h]chromen-2-one; AC1L33CH; STK691970; VU0243951-5; 2H-Furo(2,3-h)-1-benzopyran-2-one, 6-methoxy-; AKOS000277842; CHEBI:81486; SPECTRUM300005; CTK1D6743; DTXSID20197481; DivK1c_006240 |
C12H8O4 |
216.19 |
COC1=C2C(=C3C(=C1)C=CC(=O)O3)C=CO2 |
TCMBANKIN020656 |
bergagten |
|
|
|
|
TCMBANKIN022206 |
isopimpinellin |
4,9-Dimethoxy-furo[3,2-g]chromen-7-one; 7H-Furo(3,2-g)(1)benzopyran-7-one, 4,9-dimethoxy- (8CI); isopimpinellin ; MLS000876836; KBioSS_001104; Isopimpinellin, analytical standard; NCGC00095569-02; SR-01000778471-2; NSC 401288; BRD-K72253829-001-02-8; NCI60_003765; 5,9-dimethoxy-2H-furo[3,2-g]chromen-2-one; NSC401288; 7H-Furo[3,2-g][1]benzopyran-7-one,4,9-dimethoxy-; 4CN-1065; 5, 8-Dimethoxypsoralene; 7H-Furo[3,2-g][1]benzopyran-7-one, 4,9-dimethoxy-; SpecPlus_000154; KBio3_002204; 5,9-Dimethoxypsoralen; DFMAXQKDIGCMTL-UHFFFAOYSA-N; ST5308983; UNII-20GCF755G6; SMR000440593; BSPBio_002704; 4,9-dimethoxyfuro[3,2-g]chromen-7-one; 7H-Furo[3, 4,9-dimethoxy-; NSC217988; BRD-K72253829-001-03-6; 5,8-dimethoxypsoralen; DivK1c_006250; NSC-217988; CHEMBL140796; CHEBI:28853; Spectrum4_001442; I14-13386; SPECTRUM300012; TR-031106; Oprea1_593894; NSC-401288; InChI=1/C13H10O5/c1-15-10-7-3-4-9(14)18-12(7)13(16-2)11-8(10)5-6-17-11/h3-6H,1-2H3; SR-01000778471; C-14994; 4,9-Dimethoxy-7H-furo[3,2-g]chromen-7-one; KBio1_001194; Spectrum3_001232; Dimethylpsoralen; ZINC00314951; CCRIS 4347; Q-100529; ZB010380; KBio2_003672; 4,9-dimethoxy-7-furo[3,2-g]chromenone; HMS2270M12; 4,9-Dimethoxy-7H-furo(3,2-G) (1)benzopyran-7-one; NCGC00095569-01; KBioGR_001923; W1277; MFCD00017407; AN-45204; LS-70709; CC-29668; MEGxp0_000706; DFMAXQKDIGCMTL-UHFFFAOYSA-; ACon1_002361; 482-27-9; CTK4J0725; MolPort-000-882-064; C02162; SC-97796; CCG-38585; MCULE-5163280216; AKOS000278000; ST50308983; SDCCGMLS-0066520.P001; 7H-Furo(3,2-g)(1)benzopyran-7-one, 4,9-dimethoxy- (8CI)(9CI); BDBM50361386; Spectrum_000624; Spectrum2_000308; NSC 217988; STK368476; KBio2_001104; 20GCF755G6; Isopimpinellin (4,9-Dimethoxypsoralen); 5,9-dimethoxyfurano[3,2-g]chromen-2-one; 5,8-Dimethoxy-6,7-furanocoumarin; 4,9-Dimethoxy-7H-furo[3,2-g]chromen-7-one #; DTXSID30197457; FT-0603412; 4,9-Dimethoxy-7H-furo[3,2-g][1]benzopyran-7-one; I0861; BAS 00704724; Oprea1_132007; 4,9-Dimethoxyfuro[3,2-g]benzopyran-7-one; AC1Q6AY5; Spectrum5_000023; AC1L28ZK; Isopimpinellin; SPBio_000276; 5,8-Dimethoxypsoralene; 4,9-Dimethoxy-7-oxofuro[3,2-g]chromene; 5,8-Dimethoxypsoralen; SCHEMBL498907; AG-667/03555034; 4,9-Dimethoxy-7H-furo[3,2-g][1]benzopyran-7-one, 9CI; KBio2_006240; ZINC314951; NCGC00095569-03 |
C13H10O5 |
246.22 |
COC1=C2C=COC2=C(C3=C1C=CC(=O)O3)OC |
TCMBANKIN026111 |
imperinellin |
|
|
|
|
TCMBANKIN028171 |
Isobergapten |
Spectrum_000630; NCGC00095572-03; isobergapten; UNII-27X3V737WH; Spectrum5_000029; AC1L28ZS; 5-Methoxy-2H-furo(2,3-h)-1-benzopyran-2-one; SCHEMBL2253427; KBio2_001110; HMS2201F13; ZINC1846642; 2H-Furo[2,3-h]-1-benzopyran-2-one,5-methoxy-; 5-Methoxy-2H-furo[2,3-H]chromen-2-one; NCGC00095572-02; CHEBI:81487; 27X3V737WH; AC1Q6BDY; AKOS000277832; Spectrum2_000313; 5-methoxy-angelicin; KBio1_001192; C-11619; 2H-Furo[2,3-h]-1-benzopyran-2-one, 5-methoxy-; KBio2_006246; NCGC00095572-01; C18082; MEGxp0_000707; FT-0603415; Spectrum3_001226; 5-methoxyfurano[2,3-h]chromen-8-one; SpecPlus_000152; SR-01000721827; SMR000156214; 5-Methoxy-furo[2,3-h]chromen-2-one; AK144796; 2H-Furo(2,3-h)-1-benzopyran-2-one, 5-methoxy-; KBioSS_001110; 5-Hydroxyangelicin methylether; 5-methoxyfuro[2,3-h]chromen-2-one; AJ-31925; 5-methoxy-2-furo[2,3-h]chromenone; MolPort-000-882-155; KBioGR_001929; KBio2_003678; TX-017650; SR-01000721827-2; DivK1c_006248; AJSPSRWWZBBIOR-UHFFFAOYSA-N; HMS3330D17; 482-48-4; CHEMBL141690; ST24044839; ST50331507; MLS000574855; SDCCGMLS-0066519.P001; SPBio_000306; CJ-30271; 5-Methoxy-2H-furo[2,3-H]chromen-2-one #; X1164; CTK4J0734; ST5331507; DTXSID8075415; NCGC00178537-01; BSPBio_002672; SPECTRUM300032; Spectrum4_001445; 5-Methoxyangelicin; CCG-38589; 5-methoxy-2h-furo[2,3-h]chromen-2-on; MFCD00016756; KBio3_002172; BRD-K31678817-001-02-0; Isobergaptene |
C12H8O4 |
216.19 |
COC1=C2C=CC(=O)OC2=C3C=COC3=C1 |
TCMBANKIN039519 |
psoralen |
ZB004095; InChI=1/C11H6O3/c12-11-2-1-7-5-8-3-4-13-9(8)6-10(7)14-11/h1-6; 5-19-04-00445 (Beilstein Handbook Reference); s4737; A-Lactone; AK105376; 6-hydroxy-5-benzofuranacrylic acid gamma-lactone; Furocoumarin; Psoralen, >=99% (HPLC); 7H-Furo[3,2-g]chromen-7-one; KB-249864; MFCD00010520; Furo[4',5':6,7]coumarin; SMR000112587; 7H-Furo[3,2-g]benzopyran-7-one; Oprea1_841692; AKOS004110987; NSC404562; AX8034569; P2077; Manaderm (TN); AN-8451; C09305; LS-70690; Psoralene; FCH917722; EINECS 200-639-7; 6-Hydroxy-5-benzofuranacrylic acid beta-lactone; KS-00000KP0; ZCCUUQDIBDJBTK-UHFFFAOYSA-N; 7-furo[3,2-g]chromenone; ZINC120283; SC-18328; AC1L1M09; HSDB 3528; 7H-Furo[3,2-g][1]benzopyran-7-one; 2-Propenoic acid, 3-(6-hydroxy-5-benzofuranyl)-, delta-lactone; API0003973; 4CN-1081; AIDS038395; PHYTOALEXIN-CMPD; FT-0603268; Ficusin; UNII-KTZ7ZCN2EX; D00VUI; Furo[3,2-g]coumarin; 3-(6-Hydroxy-5-benzofuranyl)-2-propenoic Acid ; N1332; Psorline-P; MolPort-001-741-377; D08450; MEGxp0_001172; Furo[4',7]coumarin; 66-97-7; ANW-73223; CCRIS 4343; Psoralen; Bio-0831; SCHEMBL17835; KTZ7ZCN2EX; 5-Benzofuranacrylic acid, 6-hydroxy-, delta-lactone; CTK2F4103; Furo(3,2-g)-coumarin; Furo[2'.3':7.6]coumarin; BDBM50331544; psoralen ; 2H-furo[3,2-g]chromen-2-one; CS-3756; 7H-Furo(3,2-g)(1)benzopyran-7-one; MLS001304059; NSC-404562; TNP00293; HY-N0053; 3-(6-hydroxy-5-benzofuranyl)-2-propenoic acid delta-lactone; NCGC00017351-03; 7H-Furo[3,2-g]chromen-7-one #; AIDS-038395; furano[3,2-g]chromen-2-one; P-7850; NCGC00142529-01; NCGC00017351-02; 010P520; AC-7968; RTX-010528; 7H-Furo[3,2-g][1]benzopyran-7-one, 9CI; 6-hydroxy-5-benzofuranacrylic acid delta-lactone; CHEMBL164660; 6,7-Furanocoumarin; CHEBI:27616; NSC 404562; I06-0551; 5-Benzofuranacrylic acid, 6-hydroxy-, .delta.-lactone; C-07470; Furo(4',5',6,7)coumarin; MCULE-2236160968; 2-Propenoic acid, 3-(6-hydroxy-5-benzofuranyl)-, .delta.-lactone; Psoralene (DCF); BRD-K47264279-001-01-4; pyrano[5,6-f]benzofuran-7-one; ZINC00120283; Furo(2',3',7,6)coumarin; CC-34001; Psoralen, analytical standard; DTXSID00216205; BRN 0152784; Psolaren; ST057250; ACon1_001579; HMS2267L05; 7-furo[3,2-g][1]benzopyranone; furo[3,2-g]chromen-7-one; Furo[2',3':7,6]coumarin; P8399_SIGMA; W1301; Manaderm; 7H-furo[3,2-g]chromen-7-one; Psoralen, 97%; A835599; ST24045730; AJ-11687; NCGC00017351-01 |
C11H6O3 |
186.16 |
C1=CC(=O)OC2=CC3=C(C=CO3)C=C21 |
TCMBANKIN041262 |
isoimperatorin |
AJ-19023; Oprea1_655950; 7H-Furo[3,2-g][1]benzopyran-7-one,4-[(3-methyl-2-buten-1-yl)oxy]-; NCGC00180809-02!4-(3-methylbut-2-enoxy)furo[3,2-g]chromen-7-one; Isoimperatorin, analytical standard; 4-[(3-methylbut-2-en-1-yl)oxy]-7h-furo[3,2-g]chromen-7-one; MCULE-5468436292; Iso-imperatorin; UNII-0ZMV066080; BDBM50242377; ZB010260; BG00617053; BRD-K40367461-001-01-0; ZINC00296185; ACN-035226; HMS2268M21; CS-5801; ACon1_000176; MLS001048978; MLS000574919; API0003033; Q-100533; Oprea1_630212; 4-(3-methylbut-2-enoxy)-7-furo[3,2-g]chromenone; Iso Imperatorin; isoimperatorin ; 4-[(3-METHYLBUT-2-EN-1-YL)OXY]FURO[3,2-G]CHROMEN-7-ONE; AN-8401; CTK4J0732; I06-0434; C16976; 7,4-[(3-methyl-2-butenyl)oxy]-7H-furo[3,2-g]-1-benzopyran-7-one; AB0019796; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-((3-methyl-2-butenyl)oxy)-; AIDS-071126; SCHEMBL15090959; IGWDEVSBEKYORK-UHFFFAOYSA-N; TR-031434; 482I451; NCGC00180809-01; 482-45-1; DTXSID60197460; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-[(3-methyl-2-butenyl)oxy]-; 4-((3-methylbut-2-en-1-yl)oxy)-7H-furo[3,2-g]chromen-7-one; AK-23906; Isoimperatorin; AC1Q6AY9; KS-00000NN4; MFCD00272155; 0ZMV066080; AC-8047; AX8008744; SMR000156243; CHEMBL448060; HY-N0286; CHEBI:66071; KB-294187; FT-0656369; 10-[(3-methyl-2-butenyl)oxy]-7H-furo[3,2-g][1] benzopyran-7-one; STOCK1N-27740; ZINC296185; N1746; ST24047429; 4-[(3-Methyl-2-butenyl)oxy]-7H-furo[3,2-g]chromen-7-one #; MolPort-001-740-269; 7H-Furo(3,2-g)(1)benzopyran-7-one, 4-((3-methyl-2-butenyl)oxy)-; CI0035; V0302; 7H-Furo[3,2-g][1]benzopyran-7-one,4-[(3-methyl-2-butenyl)oxy]-; AIDS071126; 4-(3-methylbut-2-enoxy)furo[3,2-g]chromen-7-one; AKOS015895143; 4-(3-Methyl-but-2-enyloxy-furo[3,2-g]chromen-7-one; MEGxp0_000090; AC1L28ZP |
C17H16O3 |
268.307 |
c12c(c([H])c([H])o1)c(C([H])([H])\C([H])=C(/C([H])([H])[H])\C([H])([H])[H])c3c(OC(=C([H])[H])C([H])=C3[H])c2O[H] |
TCMBANKIN043913 |
psoralenol |
70522-30-4; 7-hydroxy-3-(3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-6-yl)chromen-4-one; Psoralenol; AC1NSZU1; LMPK12050036 |
C20H18O5 |
338.4 g/mol |
CC1(C(CC2=C(O1)C=CC(=C2)C3=COC4=C(C3=O)C=CC(=C4)O)O)C |
TCMBANKIN044790 |
oxypeucedanine |
oxypeucedanine |
C16H18O4 |
274.31 g/mol |
COC1CCC2C(C1)OC=C(C2=O)OC3=CC=CC=C3 |
TCMBANKIN058428 |
isopsoralen |
Sobatum; 2H-furo[2,3-h]chromen-2-one; (-)-; Furo[5',4':7,8]coumarin; 5-19-04-00447 (Beilstein Handbook Reference); 24-alpha-Ethylcholesterol; (24R)-Stigmast-5-en-3; Clionasterol; g-Sitosterol; ZINC6393492; A)-Stigmast-5-en-3-ol; NSC404563; 2H-Furo[2,3-h]-1-benzopyran-2-one; A-ol; delta5-Stigmasten-3-beta-ol; HSDB 3554; CHEBI:132823; EINECS 201-481-1; 24beta-Ethyl-5-cholesten-3beta-ol; 24S-Ethylcholest-5-en-3b-ol; CTK3E8527; Angelicin; Stigmast-5-en-3-beta-ol; 4-Hydroxy-5-benzofuranacrylic acid gamma-lactone; Angelicin (coumarin derivative); Poriferast-5-en-3beta-ol; Prostasal; CCRIS 4276; Isopsoralen; GAMMA-SITOSTEROL; AC-11107; .beta.-Dihydrofucosterol; furo[2,3-h]chromen-2-one; EINECS 201-480-6; angelicin ; (24S)-stigmast-5-en-3beta-ol; Betaprost; 24b-Ethylcholesterol; Stigmast-5-en-3-ol, (3.beta.,24S)-; 22,23-Dihydroporiferasterol; 39310-13-9; NSC 8096; Stigmast-5-en-3; 24-ethylcholest-5-en-3 beta-ol; Angelicin (coumarin deriv); ST023306; A-Ethylcholesterol; .gamma.-Sitosterol; KZJWDPNRJALLNS-OAIXMFQVSA-N; 24S-Ethylcholest-5-en-3.beta.-ol; beta-Dihydrofucosterol; Stigmast-5-en-3-ol, (3beta,24S)-; Oprea1_022970; C19654; CHEMBL393008; 2H-Furo(2,3-h)(1)benzopyran-2-one; (3-beta)-Stigmast-5-en-3-ol; ZINC00073700; AI3-26020; stigmast-5-ene-3beta-ol; LMST01040122; NSC 404563; 11027-08-0; NSC 18173; 8005-42-3; Angelicin plus ultraviolet A radiation [Angelicins]; b-Dihydrofucosterol; CCRIS 5529; (3beta,24S)-Stigmast-5-en-3-ol; CHEBI:28928; 24.beta.-Ethyl-5-cholesten-3.beta.-ol; BRN 0153970; 24.beta.-Ethylcholesterol; 24beta-Ethylcholesterol; (3S,8S,9S,10R,13R,14S,17R)-17-[(2R,5S)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; Furo(5',4':7,8)coumarin; 4736-89-4; A-Sitosterol; AC1L9X94; 2-Propenoic acid, 3-(4-hydroxy-5-benzofuranyl)-, .delta.-lactone; 2-furo[2,3-h]chromenone; Furo(2,3-h)coumarin; 2-Propenoic acid, 3-(4-hydroxy-5-benzofuranyl)-, delta-lactone; 3-(4-Hydroxy-5-benzofuranyl)-2-propenoic acid gamma-lactone; isopsoralen; 2H-Furo(2,3-H)-1-benzopyran-2-one; 5LI01C78DD; A0956_SIGMA; Angecin; Ambotz83-46-5; 24b-Ethylcholest-5-en-3b-ol; 24S-Ethylcholest-5-en-3beta-ol; UNII-5LI01C78DD; 523-50-2; 2-Oxo-(2H)-furo(2,3-h)-1-benzopyran; 83-47-6; Stigmast-5-en-3-ol, (3b,24S)-; Stigmast-5-en-3.beta.-ol, (24S)-; 5-Stigmasten-3; Fucosterol, .beta.-dihydro-; C09060; sitosterol, (3beta)-isomer; LS-1826; AKOS025401337; (24R)-Ethylcholest-5-en-3; SCHEMBL219424 |
C11H6O3 |
186.16 g/mol |
C1=CC2=C(C=CO2)C3=C1C=CC(=O)O3 |
TCMBANKIN058680 |
pabulenol |
7H-Furo(3,2-g)(1)benzopyran-7-one, 4-((2-hydroxy-3-methyl-3-butenyl)oxy)-, (R)-; DTXSID60187447; MLS002472950; pabulenol ; BVMOMQJYQYBMKL-LBPRGKRZSA-N; HMS2198I04; CHEMBL1870203; R-(+)-Pangelin; 33783-80-1; SMR001397058; 4-[[(R)-2-Hydroxy-3-methyl-3-butenyl]oxy]-7H-furo[3,2-g][1]benzopyran-7-one; Pangelin; {5-[2'(R)-Hydroxy-3'-methyl-3'-butenyl-oxy]furocoumarin}; 4-[(2S)-2-hydroxy-3-methylbut-3-enoxy]furo[3,2-g]chromen-7-one; 4-[(2S)-2-hydroxy-3-methylbut-3-enoxy]-7-furo[3,2-g]chromenone; 4-[(2S)-2-hydroxy-3-methyl-but-3-enoxy]furo[3,2-g]chromen-7-one; AIDS210292; AIDS-210292; {5-[2''(R)-Hydroxy-3''-methyl-3''-butenyl-oxy]furocoumarin} |
C16H14O5 |
286.28 g/mol |
CC(=C)C(COC1=C2C=CC(=O)OC2=CC3=C1C=CO3)O |
TCMBANKIN059085 |
oxypeucedanin hydrate |
NCGC00169070-01; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-(2,3-dihydroxy-3-methylbutoxy)-; HMS2267N05; NCGC00169070-02!4-(2,3-dihydroxy-3-methylbutoxy)furo[3,2-g]chromen-7-one; 7H-Furo[3,2-g][1]benzopyran-7-one,4-(2,3-dihydroxy-3-methylbutoxy)-; MCULE-8387217181; BAS 00704766; 24724-52-5; 4-(2,3-Dihydroxy-3-methylbutoxy)-7H-furo[3,2-g]chromen-7-one; AC1LA8IU; oxype-ucedanin hydrate; MEGxp0_000084; 4-(2,3-Dihydroxy-3-methylbutoxy)-7H-furo[3,2-g]chromen-7-one #; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-[(2R)-2,3-dihydroxy-3-methylbutoxy]-; BRD-A22947368-001-01-7; oxypeucedanin hydrate ; PEWFWDOPJISUOK-UHFFFAOYSA-N; CTK0J4642; Oprea1_667233; 4-(2,3-Dihydroxy-3-methylbutoxy)furo(3,2-g)chromen-7-one; MolPort-000-761-123; Oprea1_033750; MLS000877013; AC1Q6AYA; AKOS003601375; 4-(2,3-Dihydroxy-3-methyl-butoxy)-furo[3,2-g]chromen-7-one; SCHEMBL15944413; Hydrated oxypeucedanin; NP-000248; 4-(2,3-dihydroxy-3-methyl-butoxy)furo[3,2-g]chromen-7-one; SMR000440613; ACon1_000447; CHEMBL1438253; HMS3347D15; 4-(2,3-dihydroxy-3-methylbutoxy)furo[3,2-g]chromen-7-one; DTXSID10333114; (+/-)-Prangol;4-[(2S)-2,3-dihydroxy-3-methylbutoxy]-7-furo[3,2-g]chromenone; 4-[(2S)-2,3-dihydroxy-3-methyl-butoxy]furo[3,2-g]chromen-7-one; ZINC00477939;(s)-(?)-oxypeucedaninhydrate;aviprin;(+)-oxypeucedanin hydrate |
C16H16O6 |
304.29 g/mol |
CC(C)(C(COC1=C2C=CC(=O)OC2=CC3=C1C=CO3)O)O |
TCMBANKIN059131 |
isooxypeucedanin |
pabulenone; isooxypeucedanine |
C16H14O5 |
286.28 g/mol |
CC(C)C(=O)COC1=C2C=CC(=O)OC2=CC3=C1C=CO3 |
TCMBANKIN061695 |
Majudin |
Spectrum2_000534; 5-19-06-00004 (Beilstein Handbook Reference); 4-methoxyfuro[3,2-g]chromen-7-one; Spectrum3_000663; KBio3_001545; CCRIS 4348; KBioGR_002055; 4-methoxy-7-furo[3,2-g]chromenone; DivK1c_000529; NCGC00091582-01; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-methoxy-; KBio2_001274; TNP00299; NINDS_000529; Bergapten; Spectrum5_000155; EINECS 207-604-5; KBio1_000529; 4-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; KBioSS_001274; ACon0_000984; AIDS031096; 4-methoxy-7H-furo[3,2-g]chromen-7-one; HSDB 3466; 5-Methoxypsoralen; Spectrum_000794; KBio2_003842; BSPBio_002325; MEGxp0_000990; 65320_FLUKA; BRN 0019560; 5-Mop; 6-Hydroxy-4-methoxy-5-benzofuranacrylic acid, gamma-lactone; NCGC00091582-02; Bergaptene; 5-Methoxy psoralen; NCI60_042121; 5-Methoxy-6,7-furanocoumarin; KBio2_006410; 4-Methoxy-furo[3,2-g]chromen-7-one; IDI1_000529; Bergapten(e); BAS 00674110; ACon1_001979; SPBio_000547; 5-Methoxypsoralen with ultraviolet A therapy; BERGAPTAN; Psoraderm; SDCCGMLS-0066492.P001; NSC95437; 7H-Furo(3,2-g)(1)benzopyran-7-one, 4-methoxy-; ST057259; ZINC00057731; InChI=1/C12H8O4/c1-14-12-7-2-3-11(13)16-10(7)6-9-8(12)4-5-15-9/h2-6H,1H; C01557; Heraclin; NCGC00091582-03; 4-Methoxyfuro[3,2-g]benzopyrane-7-one; 275727_ALDRICH; Spectrum4_001478; SPECTRUM300546; O-Methylbergaptol; 5-Methoxyfuranocoumarin; NSC 95437; NCGC00017357-01; AIDS-031096; 484-20-8; Oprea1_562364; 5-methoxypsoralen; bergapten;5-19-06-00004 (Beilstein Handbook Reference); AB00052148_06; V0122; DivK1c_000529; NCGC00259906-01; KBio2_001274; EINECS 207-604-5; Geralen; SR-05000002173; KBio1_000529; KBioSS_001274; Majudin; 4-Methoxy-7H-furo[3,2-g]chromen-7-one #; 4-Methoxy-7H-furo[3,2-g]chromen-7-one; HMS501K11; 5-Methoxypsoralen, 99%; SMR000112435; NCGC00017357-03; NCGC00017357-07; CAS-484-20-8; B2840; AK134854; KS-00000GSD; TR-017690; Bergapten(e); NCGC00017357-04; BAS 00674110; CC-24574; C-11626; BERGAPTAN; Psoraderm; D07521; SDCCGMLS-0066492.P001; BRD-K12968785-001-03-4; MLS002207272; 5-Methoxypsoralen (Bergapten); InChI=1/C12H8O4/c1-14-12-7-2-3-11(13)16-10(7)6-9-8(12)4-5-15-9/h2-6H,1H; Bergaptene (DCF); 5-methoxy-psoralen; Pentaderm (TN); SPECTRUM300546; HY-N0370; ANW-42611; 5-Methoxypsoralen (obsol.); 5-Methoxy psoralen; KBioGR_002055; Oprea1_562364; Tox21_303255; NCGC00178705-02; Q-100536; Spectrum3_000663; BRD-K12968785-001-02-6; 4-methoxy-7H-furo[3,2-g][1]benzopyran-7-one; NCGC00017357-08; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-methoxy-; ZINC57731; TNP00299; Bergapten; BDBM50067880; Spectrum5_000155; NSC755877; 4-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; AB00052148_07; DS-2970; Spectrum_000794; KBio2_003842; 5-methoxy-2H-furo[3,2-g]chromen-2-one; BRN 0019560; NCGC00178705-01; 5-Mop; UNII-4FVK84C92X; M-9412; NCGC00091582-02; HMS2268M24; CHEBI:18293; CS-2234; 5 methoxypsoralen; 5-methoxypsoralen ; 5-Methoxy-6,7-furanocoumarin; KBio2_006410; NCGC00017357-05; SR-05000002173-5; CCG-39946; 5-Methoxypsoralen with ultraviolet A therapy; DSSTox_CID_5560; NSC95437; CJ-00484; 7H-Furo(3,2-g)(1)benzopyran-7-one, 4-methoxy-; ST057259; 6-Hydroxy-4-methoxy-5-benzofuranacrylic acid, .gamma.-lactone; NCGC00017357-02; N1304; AC1Q47BC; NCGC00091582-03; SBI-0051583.P002; 4-Methoxy-7H-furo[3,2-g]benzopyran-7-one; NSC 95437; 5-methoxyfurano[3,2-g]chromen-2-one; bergaptene; 484-20-8; CTK3J2399; s4239; Spectrum2_000534; Pentaderm; 4FVK84C92X; KBio3_001545; HMS3652F19; ST2411501; NINDS_000529; STK333038; MCULE-7768334865; NCGC00017357-06; HSDB 3466; 5-Methoxypsoralen; BSPBio_002325; CB-1199; 6-Hydroxy-4-methoxy-5-benzofuranacrylic acid, gamma-lactone; BGEBZHIAGXMEMV-UHFFFAOYSA-N; I14-13388; MFCD00010272; bmse000758; IDI1_000529; AB0019675; DB12216; 4-Methoxyfuro[3,2-g]benzopyrane-7-one; 4-Methoxyfuro[3,2-g]benzopyran-7-one; O-Methylbergaptol; 484B208; RTR-017690; NCGC00091582-04; SC-46077; AKOS000276715; SR-05000002173-3; CCRIS 4348; DSSTox_GSID_25560; 4-methoxyfuro[3,2-g]chromen-7-one; ZB002242; DTXSID1025560; NSC-755877; NCGC00091582-01; 5-methoxypsoralene; AX8014410; A827532; AJ-09777; ACon0_000984; Tox21_202357; HMS1923G13; FT-0603416; MEGxp0_000990; AC1L1DHU; MolPort-000-880-879; NSC-95437; 4CN-0945; NCI60_042121; BG01521510; 4-Methoxy-furo[3,2-g]chromen-7-one; NCGC00256998-01; AC-20189; CHEMBL24171; SPBio_000547; ACon1_001979; DSSTox_RID_77830; 7H-Furo[3, 4-methoxy-; SR-05000002173-2; Bergapten, analytical standard; SCHEMBL50066; 4-methoxy-7-furo[3,2-g][1]benzopyranone; Heraclin; C01557; Bio-0829; Spectrum4_001478; LS-1292; D0QR5G; Pharmakon1600-00300546; 5-Methoxyfuranocoumarin; MLS002454380; NCGC00017357-01; AN-9448 |
C12H8O4 |
216.19 g/mol |
COC1=C2C=CC(=O)OC2=CC3=C1C=CO3 |